Antimicrobial susceptibility studiesSynergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia
Introduction
Multidrug-resistance of Gram-negative nosocomial isolates has become a problem in everyday clinical practice particularly in the ICU (Hanberger et al., 2001). Stenotrophomonas maltophilia is a pathogen affecting immunocompromized and delibitated patients (Denton & Kerr, 1998). That species is intrinsically resistant to most ÎČ-lactams, quinolones and aminoglycosides; trimethoprim/sulfamethoxazole is considered the treatment of choice for infections by these isolates (Berg et al., 1999). Isolates resistant to trimethoprim/sulfamethoxazole rarely emerge (Gales et al., 2001a) but whenever they occur the available therapeutic alternatives are limited.
Colistin is an old antimicrobial belonging to polymyxins that has been proposed as an adequate therapeutic alternative for infections by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii (Levin et al., 1999). Its application is however limited due to its high toxicity and poor pharmacokinetics. Polymyxins have been shown to possess a considerable in vitro activity on S. maltophilia Gales et al 2001b, Giacometti et al 2000. Based on the in vitro synergy of colistin and rifampin on multidrug-resistant Acinetobacter baumannii (Giamarellos-Bourboulis et al., 2001), the present study aimed to the interaction of colistin with rifampin or trimethoprim/sulfamethoxazole against nosocomial isolates of S. maltophilia resistant to trimethoprim/sulfamethoxazole.
Section snippets
Selection of isolates
A total of 24 S. maltophilia clinical isolates were applied. All were derived from seven different hospitals of the territory of Athens and isolated from different patients with nosocomial infections. The biologic source of isolation was as follows: sputum 11; urine 9; pus 2; blood 2. Identification was performed by the API20E system (bioMĂ©rieux, Marcy Lâ Etoile, France). Inclusion criterion was high resistance to amplicillin/sulbactam (MIC > 64/4ÎŒg/ml), to trimethoprim/sulfamethoxazole (MIC >
Results
MIC50 and MIC90 of colistin were 4 and 16ÎŒg/ml respectively. Seventeen isolates (70.8%) were inhibited at the susceptibility breakpoint of 4ÎŒg/ml Gales et al 2001b, Giamarellos-Bourboulis et al 2001, whereas the remaining seven isolates were inhibited at MICs equal to 8 or 16ÎŒg/ml. Changes of viable cell counts by the interaction of colistin and rifampin on S. maltophilia are shown in Table 1. Synergy of 1Ă MIC of colistin with rifampin was found in 16 (66.7%), 14 (58.3%), 14 (58.3%) and 13
Discussion
S. maltophilia is characterized by intrinsic resistance to a wide variety of antimicrobial agents and trimethoprim/sulfamethoxazole is the most active antimicrobial on that species Betriu et al 2001, Valdezate et al 2001. Since isolates resistant to trimethoprim/sulfamethoxazole seem to emerge over the last years in the ICUs Hanberger et al 2001, Tsiodras et al 2000, the present study investigated the activity of the interactions of colistin with rifampin or trimethoprim/sulfamethoxazole on 24
References (16)
- et al.
Surveillance of antibiotic resistance in European ICUs
J Hosp Infect
(2001) - et al.
Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii
Diagn Microbiol Infect Dis
(2001) - et al.
In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate
Clin Microbiol Infect
(2000) - et al.
Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia
Antimicrob Agents Chemother
(1999) - et al.
Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993â1999
J Antimicrob Chemother
(2001) - et al.
Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia
Clin Microbiol Rev
(1998) Rifamycins
- et al.
Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patientsgeographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1907â1999)
Clin Infect Dis
(2001)